Shots:

• The companies collaborate for the evaluation of novel candidates with Arcus’s AB928 utilizing the MORPHEUS P-Ib/II platform with upfront randomization versus control groups in two studies. The companies will supply its anti-cancer agents and will jointly find the studies
• The two studies are: The first study will assess AB928 + Tecentriq + regorafenib- Tecentriq + regorafenib vs regorafenib monothx in patients with 3L mCRC; the second study will assess AB928 + atezolizumab + gemcitabine/nab-paclitaxel vs gemcitabine/nab-paclitaxel in patients with 1L mPDAC
• AB928 is the novel dual adenosine A2aR/A2bR receptor antagonist designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and is being evaluated in P-Ib/II across multiple indications

Click here to read full press release/ article | Ref: PRNewswire | Image: WSJ